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Abstract.  Using synthetic peptides, we have identified 
two distinct regions of the glycoprotein SPARC 
(Secreted Protein Acidic and Rich in Cysteine) (os- 
teonectin/BM-40) that inhibit cell spreading.  One of 
these sites also contributes to the affinity of SPARC 
for extracellular matrix components.  Peptides 
representing  subregions of SPARC were synthesized 
and antipeptide antibodies were produced.  Immuno- 
globulin fractions of sera recognizing an NH2-terminal 
peptide (designated  1.1) blocked SPARC-mediated anti- 
spreading activity. Furthermore,  when peptides were 
added to newly plated endothelial cells or fibroblasts, 
peptide 1.1 and a peptide corresponding to the COOH 
terminal  EF-hand domain (designated 4.2) inhibited 
cell spreading in a dose-dependent manner.  These pep- 
tides exhibited anti-spreading  activity at concentrations 
from 0.1 to 1 mM.  The ability of peptides 1.1 and 4.2 
to modulate cell shape was augmented by an inhibitor 
of protein synthesis and was blocked by specific anti- 
peptide immunoglobulins.  In addition to blocking cell 
spreading,  peptide 4.2 competed for binding of 
[12q]SPARC and exhibited differential affinity for ex- 
tracellular matrix molecules in solid-phase binding as- 
says.  The binding of peptide 4.2 to matrix components 
was Ca++-dependent  and displayed specificities similar 
to those of native SPARC.  These studies demonstrate 
that both anti-spreading  activity and affinity for colla- 
gens are functions of unique regions within the 
SPARC amino acid sequence. The finding that two 
separate regions of the SPARC protein contribute to its 
anti-spreading  activity lead us to propose that multiple 
regions of the protein act in concert to regulate the in- 
teractions of cells with their extracellular matrix. 
THOUGH our understanding  of the molecular bases of 
cell attachment and spreading has increased appreci- 
ably,  the processes that regulate these phenomena 
are complex and less well defined.  It is clear that cellular 
adhesion is a  dynamic phenomenon.  Migratory or trans- 
formed cells have fewer focal contacts and exhibit reduced 
spreading as compared to stationary or nontransformed cells. 
In nontransformed cells, focal contacts disassemble during 
mitosis and cell migration, with a resultant temporary change 
in cell shape (Burridge  et al.,  1988; Couchrnan  and Rees, 
1979;  Woods and Couchman,  1988).  Molecules that have 
been implicated as regulators of cell shape because of their 
effects on focal contacts include proteases, growth factors, 
phorbol esters, and agents that increase intracellular  cAMP 
(Burridge et al., 1988; Herman and Pledger,  1985; Herman 
et al.,  1987; Schliwa et al.,  1984). In addition,  several ex- 
tracellular  glycoproteins  have  recently been described as 
anti-spreading  factors; i.e., proteins that regulate  the adhe- 
sive characteristics of cells by altering contacts between cells 
and their extracellular  matrix. 
SPARC  1 (osteonectin/BM-40),  a  developmentally regu- 
lated, secreted glycoprotein, is associated with cellular events 
requiring tissue remodeling,  cell movement, and/or prolifer- 
ation (Termine et al.,  1981; Holland et al.,  1987; Howe et 
al.,  1988; Wewer et al.,  1988; Mason et al.,  1986b; Mann 
et al.,  1987; Sage et al.,  1984; Sage et al.,  1989a).  Levels 
of SPARC protein are elevated in response to cellular injury 
after endotoxin treatment,  or as a result of culture shock 
(Sage et al., 1986). Recently, SPARC has been shown to in- 
duce cell  rounding  in  spread monolayers  of cultured en- 
dothelial  cells and fibroblasts  (Sage et al.,  1989b) and may 
thus be classified,  along with thrombospondin (Tsp) (Lahav, 
1988;  Murphy-Ullrich  and  H66k,  1989)  and  tenascin 
(Chiquet-Ehrismann  et al., 1988), as a negative mediator of 
cellular spreading.  The actions  of these glycoproteins  are 
distinct  from those of adhesive proteins such as fibronectin 
and laminin. 
While our information is limited, the mechanisms by which 
Tsp, tenascin,  and SPARC influence spreading  appear to be 
different. Tsp and tenascin have both adhesive and anti-adhe- 
A portion of this work was presented in poster form at the 1989 American 
Society for Cell Biology meeting in Houston, TX and appears in abstract 
form (Lane, T. E, and E. H. Sage.  1989. J.  Cell Biol.  109:16a). 
1. Abbreviations used in this paper: BAEC, bovine aortic endothelial cell; 
CHX,  cycloheximide;  FCLF,  fetal  calf  ligament  fibroblast;  SPARC, 
secreted protein acidic and rich in cysteine; Tsp, thrombospondin. 
© The Rockefeller University Press, 0021-9525/90/12/3065/12  $2.00 
The Journal of Cell Biology, Volume 111 (No. 6, Pt. 2), Dec. 1990  3065-3076  3065 sire properties that may be cell-specific (Chiquet-Ehrismann 
et al.,  1988; Kruse et al.,  1985; Lahav,  1988; Lahav et al., 
1987; Tuszynski et al., 1987). Recently, unique adhesive and 
anti-adhesive regions have been identified in tenascin with 
fragments of the recombinant protein (Spring et al.,  1989). 
The effects of Tsp, which contains an RGD sequence (Lawler 
and Hynes, 1986), are apparently mediated via specific cell 
surface integrins  (Lawler et al.,  1988).  Although tenascin 
has  no RGDS sequences,  both Tsp and tenascin  interfere 
with the binding of fibronectin to cells (Chiquet-Ehrismann 
et ai.,  1988; Lahav et al., 1987). In contrast, SPARC has no 
demonstrated adhesive characteristics for cells and disrupts 
spreading  in  a  variety  of cultured  cell  strains.  This  anti- 
spreading activity of SPARC appears to act by an integrin in- 
dependent pathway (Sage et al.,  1989b). That Tsp binds to 
SPARC with a Kd of 0.7 nM (Clezardin  et al.,  1988) sug- 
gests the possibility of an integrated regulatory pathway. 
Synthetic peptides have now been used by a number of in- 
vestigators to identify functional regions of complex proteins 
(Stewart and Young,  1984).  The identification  of adhesive 
regions of fibronectin (Ruoslahti and Pierschbacher,  1986; 
Ruoslahti and Pierschbacher,  1987; Dufour et al., 1988) and 
laminin (Grafet al., 1987a,b; Tashiro et al., 1989; Kleinman 
et ai., 1989) demonstrated the feasibility of peptide reagents 
for  studying  cell-substrate  adhesion.  Important  contribu- 
tions have also been made in the identification of receptor 
binding  sites  (Morris  et al.,  1990) and in the analysis of 
specific amino acids involved in ligand binding sites (Parraga 
et al.,  1990; Reid, 1990). In addition, peptide immunogens 
have proven valuable for the production of antisera against 
molecules  for  which  sequence  information  was  available 
(Tamura et al.,  1983; Kamboj et al.,  1989). 
Here we report that antibodies raised against a peptide from 
the NHe-terminai region of SPARC block SPARC-mediated 
anti-spreading activity. In addition, both the same NH2-ter- 
minal  peptide and a peptide derived from the COOH-ter- 
minal  Ca++-binding  site inhibit  cell spreading  specifically. 
These results support the idea that SPARC acts via a Ca  ++- 
dependent mechanism to modulate cell attachment (Sage et 
al.,  1989b). We propose that this anti-spreading activity re- 
suits from disruption of cell-substrate contacts and the sub- 
sequent reorganization of cytoskeletal elements. The synthe- 
sis and release of SPARC may be one of the options available 
to cells in the process of diminishing  adhesive interactions 
with their substrates.  The functional consequences of such 
actions include the regulation of cell shape, migratory poten- 
tial,  and the ability to divide. 
Materials and Methods 
Peptide Synthesis and Labeling 
A series of 20-mers representing regions of the mouse SPARC amino acid 
sequence were synthesized by Dr. Patrick Chou (Howard Hughes Medical 
Table 1. Diagrammatical Representation of  the SPARC Protein and the Location of  Synthetic Peptides 
with Their Relative Anti-Cell Spreading Activities 
A 
I  II  Ill  IV 
Domains  Ca++-Binding  Cysteine  Helical  Ca++-Binding 
Rich  Domain 
I 
l 
NH 2 
1.1 
1.3 
2.1 
2.3 
3.2 
3.4 
I 
ClIO 
["  COOH 
I 
/ 
m 
4.2  l 
Anti-spreading  +  --  ~  D  +  I 
i 
ND 
I 
Sequence 
1 mMI280  B  Peptide  Sequence  location  E1 ~m 
1.1  QTEVAEEIVE  EETVVEETGV  5-23  1.28* 
1.3  QVEMGEFEDG  AEETVEEVVA  31-50  1.28" 
2.1  CQNHHCKHG  KVCELDESNTP  54-73  0.36 
2.3  TLEGTKKGHK  LHLDYIGP  113-130  1.28 
3.2  KNVLVTLYER  DEGNNLLTEK  154-173  1.28 
3.4  NEKRLEAGDI  PVELLARDFE  184-203  1.28" 
4.2  T CDLDNDKYI  ALEEWAC~FG  254-273  7.21 
(.4) Peptides are named with reference to the predicted domain structure of routine SPARC (Engel et al., 1987).  (+) Inhibition of spreading; (-) no inhibition 
observed; (ND), not determined. Bars indicate 20 amino acids. (B) Sequences of synthetic peptides used in these experiments. Sequences were derived from the 
predicted amino acid sequence of murine SPARC (Mason et al.,  1986a).  To determine peptide concentration, extinction coefficients (E] ~mo) were calculated 
based on amino acid composition (Gill and yon Hippel, 1989).  Cysteine residues are underlined. (*) Extinction coefficients  derived for peptides synthesized with 
an additional NH2-terminal  tyrosine residue. The single letter amino acid code has been used. 
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moGenetics Corp., Seattle,  WA). Peptides  were synthesized  using either 
t-boc or f-moc chemistry (Applied BioSystems Inc., Foster City, CA). An 
NH2-terminal Tyr residue was added in some cases to allow for iodination 
of the peptide.  The location and amino acid sequences of the peptides used 
in this study are shown in Table I. Sequences were derived and numbered 
from the predicted amino acid sequence of mature mouse SPARC after 
removal of the signal sequence (Mason et al,,  1986a).  Thus, Alats of pre- 
SPARC is considered to be Alal of the mature protein. Peptide nomencla- 
ture is based on the four structural regions deduced from the amino acid 
sequence (Engel et al., 1986). Thus, peptides  1.1 and 1.3 represent 20-mer 
peptides derived from the NH2-terminal region I. Peptides 2.1 and 2.2 are 
derived from region 2, etc. 
Purity and homogeneity were achieved by analytical HPLC on a PRP-3 
column (Hamilton Co., Reno, NV) with a linear gradient of 0-30 % acetoni- 
trile in 50 mM NaOH and 0.1% trifluoroacetic  acid. For some experiments, 
peptides were purified on a semipreparative PRP-3 column with similar gra- 
dients in a 20 mM NH4HCO3 (pH 8.5)  buffer.  HPLC-purified  peptides 
were lyophilized repeatedly to remove salts before use in cell culture experi- 
ments. Peptides were solubllized in dilute NaOH and neutralized with PBS 
(10 mM phosphate, pH 7.5, 150 mM NaC1). For some experiments, peptides 
1.1, 3.2,  and 4.2 were labeled with Na[125I] using Iodogen  according to 
protocols described by the supplier (Pierce Chemical Co., Rockford,  IL). 
Specific activity was ,~300 cpm/fmole peptide, but slight variations for each 
peptide were noted. Amino acid composition and concentration of peptide 
stock solutions were performed by amino acid analysis  (ZymoGenetics 
Corp., Seattle, WA). Alternatively, peptide concentrations were determined 
by optical density using extinction coefficients calculated  for each peptide 
(Gill and yon Hippel,  1989) (Table I). 
Cells and Cell Culture 
All cells were maintained in DME medium (Gibco Laboratories, Grand Is- 
land, NY) containing 10% by volume  FCS and antibiotics (Sage et al., 
1989b).  Primary cultures of bovine aortic endothelial cells (BAEC) were 
isolated  as described by Schwartz  (1978).  Primary cultures of fetal calf 
ligamentum nuchae fibroblasts (FCLFs) (Sage and Mecham, 1982) were a 
gift of Dr. L. Fonser (University of Washington, Seattle, WA). Cells, used 
between passages  3 and 8, were thawed from stocks  maintained in liquic[ 
N2 and were passaged with trypsin/EDTA (Sage et al., 1989b). The mouse 
parietal yolk sac endodermal line PYS-2 was a gift from Dr. J. Lehman (Al- 
bany Medical College,  Albany,  NY). 
Antibody ~oduction and Characterization 
Peptides were selected for antibody production based on our interest in their 
Ca++-binding properties (1.1, 1.3, and 4.2) or based on predicted antigenic- 
ity. Antigenicity  was assessed by the hydrophllicity  algorithm of Hopp and 
Woods (1981). The sequence YERDEG (aa 161-166) contained within pep- 
tide 3.2 proved to have the highest hydrophilic character by these calcula- 
tions.  Peptides  were conjugated to keyhole  limpet hemocyanin (Sigma 
Chemical Co., St. Louis,  MO) with carbodiimide (Story Chemical Corp., 
Muskegon, MI), according to protocols by which the amino (N-KLH)- or 
carboxy (C-KLH)-terminal residue is preferentially cross-linked (Tamura et 
al.,  1983).  Female New Zealand White rabbits were injected every 2 wk 
with 3  rag of a mixture of N-KLH, C-KLH,  and free peptide (1:1:1) in 
Freund's adjuvant (Sigma Chemical Co.).  Addition of tracer amounts of io- 
dinated peptides suggested that 5-20 tool of peptide were bound per mole 
KLH  (data  not  shown).  Immunoglobulin  fractions  were  prepared  by 
precipitation of whole sera with 20% ammonium sulfate (wt/vol) ratio, and 
precipitates were dialyzed against PBS. 
Titer and specificity of antisera were monitored by an ELISA in conjunc- 
tion with an alkaline-phosphatase goat anti-rabbit IgG detection system as 
previously described (Sage et al., 1984). Peptides were conjugated to rabbit 
serum albumin (Sigma Chemical Co._)with~utar~deh£de (Harlow  and 
Lane, 1988). Anti-peptide antisera were assayed for binding to homologous 
and heteroiogous peptide-rabbit serum albumin conjugates and to a variety 
of purified  proteins. 
Immune Precipitation of  SPARC 
Immunoprecipitations  from ceil culture supernatants ~re performed as pre- 
viously described (Sage et al., 1984) with a few modifications.  Subconfluent 
monolayers  of PYS-2  cells were incubated with 20/tel [3sS]Met/ml  for 
18 h in media lacking Met. Media were centrifuged at 12,000 g to remove 
cell debris, and a mixture of protease inkibitors was added (final concentra- 
tions: 0.25 mM EDTA, 5 mM N-ethylmaleimide,  0.1/~g/mi pepstatin A, 
0.4 mM PMSF).  Proteins in the media  were  preabsorbed with protein 
A-Sepharose (Pharmacia-LKB,  Piscataway, NI) to reduce nonspecific bind- 
ing. Antibodies were added and immune complexes were precipitated with 
protein A-Sepharose.  Precipitates were washed three times, and immune 
complexes  ware released with SDS-PAGE buffer at 95°C (0.1 M Tris-HC1 
pH 6.8(2%  SDS,  1 M  urea,  10%  glycerol)  (Laemmli,  1970).  Proteins 
released  from protein A were reduced with 50 mM lIFT and heated 1-3 
min at 95°C.  SDS-PAGE was performed on discontinuous acrylamide gels 
(4% stacking and 12.5% separating gels) at25 mA. Molecular weight stan- 
dards (Bethesda Research Laboratories, Gaithersburg, MD) included myo- 
sin H-chain (200 kD), phosphorylase b (97.4 kD), BSA (68 kD), chicken 
egg albumin (43 kD), cechymotrypsinogen (27.5 kD), and lysozyme (14.6 
kD).  Gels were fixed  and stained with Coomassie brilliant blue R-250 
(0.25% in 45% methanol, 9% acetic acid). Destained gels were treated with 
2,5-diphenyloxazole  in DMSO  and dried before  exposure  to x-ray  film 
(X-Omat-RP,  Kodak) at -70°C. 
Antibody Specificity for Proteolytic Fragments 
of  SPARC 
SPARC was purified to >95 % homogeneity from PYS cell culture medium 
as described by Sage et al. (1989b).  5/~g of SPARC was suspended in 20 
/zl TBS (50 mM Tris-HCl,  pH 7.5, 150 mM NaC1) and treated for 30 rain 
at 37°C with buffer alone, 0.1 #g TPCK-trypsin  (Worthington Diagnostics, 
Freehold, NJ), or 2 ~g TPCK-trypsin.  The reaction was stopped with a 100- 
fold molar excess of soybean trypsin inhibitor (Sigma Chemical Co.) and 
SDS-PAGE buffer. Fragments were reduced with DTT, resolved by SDS- 
PAGE (4% stacking gel, 12.5%  and 20% separating gels), and transferred 
to nitrocellulose  (BA-85; Schleicher & Schueil Inc., Keene,  NH). Trans- 
ferred proteins were stained with amido black (Bio-Rad Laboratories, Rich- 
mond, CA), blocked in MT-buffer (PBS containing 1% nonfat dried milk, 
0.05% Tween-20; Bio-Rad Laboratories), and incubated with antibodies as 
described in the figure legends. In some cases, antibodies were preincubated 
with MT-buffer containing 0.2 mM free peptide (Sage et al.,  1989b). 
Neutralization of SPARC Activity with 
Anti-peptide Antibodies 
SPARC  protein  (10-20 tzg/ml)  was  preincubated with  500  #g/ml  of a 
purified immunoglobulin fraction from each antiserum (see above). BAEC 
were plated for 24 h as described above, except that the serum used was 
depleted  of complement by heating at 55°C for 1 h. SPARC alone,  or as 
immune complexes,  was then added  to BAEC and cell morphology was 
monitored for 24 h. 
Effects of  SPARC Peptides on Cellular Morphology 
BAEC and FCLF were cultured as described above. Morphological effects 
of SPARC and peptides were determined by two procedures.  (a) Cells were 
trypsinized, washed in 10% FCS/DME, washed in 1% FCS/DME, and sub- 
sequently  plated on 24- or 48-well plates of tissue culture plastic (Costar, 
Cambridge, MA) in the presence of SPARC (1-40 ~g/ml) or peptides (0.1-2 
re_M). For some experiments, peptides were pre~cubated with anti-peptide 
antibodies. Control experiments showed that spreading was not inhibited by 
antibodies alone. (b) Trypsinized cells were plated for 24 h on glass cham- 
ber slides (Lab-Tek, Nunc, Inc., Naperville,  IL) in 10% FCS/DME. Cells 
were washed in serum free-DME and peptides added as above. Media were 
replaced  with fresh  10%  FCS/DME containing 5  #g/ml cycloheximide 
(CHX/DME; Sigma Chemical Co.) for 1 h after which peptides diluted in 
CHX/DME were added in fresh media to the cells.  Cell morphology was 
assessed  by visual inspection using an inverted  phase photomicroscope 
(Carl Zeiss Inc.) and the images recorded on Ektachrome film (ET 135, 160 
ASA; Kodak). Cells surrounded by a halo of refractility, as compared to un- 
treated cells plated under similar conditions, were classified as "rounded7 
For quantitation of anti-spreading activity of peptides on freshly plated 
cells (procedure 1), a scoring system was devised to characterize the degree 
of spreading within a group of cells.  Unattached cells were removed by 
washing and the culture was photographed as above. Cell counts were deter- 
mined and cells were scored as (a) spread,  flatter.ed ceils with diminished 
cellular refractility; (b) unspread, rounded cells projecting short processes 
in the initial stages of spreading;  and (c) round, highly refractile  cells with 
no apparent processes.  Cells representative of these three groups are indi- 
cated in Fig. 4. The number of cells in each group was then converted into 
a "rounding index" by the formula:  rounding index =  [(1  × a) +  (2  x  b) 
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tainlng 0.1%  ovalbumin (Badet  et ai.,  1989).  12sI-Labeled  SPARC  was 
added to wells containing substrate-adsorbed proteins for 4-12 h, at 4°C. 
Wells were washed three times with Hepes binding buffer and bound radio- 
activity was measured by a gamma counter (Beckman Instruments Inc., 
Palo Alto, CA). Assays were done in triplicate and values graphed as the 
mean  +  SD. To determine specific binding, excess unlabeled ligand was 
mixed with labeled ligand before addition to substrate-coated wells. In com- 
petition assays, label was mixed with individual peptides before addition to 
wells. 
To determine whether peptides would bind extracellular matrix compo- 
nents directly, purified proteins wore plated in microtiter wells and excess 
binding sites blocked with TBS containing  1%  ovalbumin.  125I-Labeled 
peptides were then added for 4-12 h, at 4°C with or without 5 mM CaCl2; 
unbound radioactivity was removed with TBS containing 5 mM CaCl2 and 
1% ovalbumin. Quantitation of substrate protein bound to plates was per- 
formed by amino acid analysis of material solubilized by constant boiling 
HCI at ll0°C. Bound radioactivity was corrected for pmoles of substrate 
on each well. Assays were done in triplicate, and values were graphed as 
the mean  +  SD. 
Figure/. Anti-peptide 1.1 IgG precipitates SPARC from tissue cul- 
ture media. PYS cells were labeled for 12 h with [35S]Met, and the 
media were centrifuged and treated with protease inhibitors. Pro- 
teins were resolved by SDS-PAGE of (lane 1) unfractionated me- 
dia; (lane 2) anti-SPARC immunoprecipitate; (lanes 3 and 4) an- 
tipeptide 1.1 immunoprecipitate, serum from two different rabbits; 
(lanes 5 and 6) anti-peptide 4.2 immanoprecipitate, serum from 
two different  rabbits. Proteins were resolved in the presence of DTT 
and were visualized by fluorescent autoradiography. Arrow indi- 
cates the location of the SPARC doublet. 
+  (3  x  c)]i(a +  b  +  c), where a, b, and c are the number of cells in each 
group. An index of 1 thus represents a culture with only spread cells. A cul- 
ture with increasing numbers of unspread and round cells would approach 
the maximum rounding index of 3. Values were calculated for two indepen- 
dent cultures and graphed as the average +  SE. 
Binding to Purified Extracellular Proteins 
Solid-phase binding assays were conducted in polystyrene microtiter wells 
as previously described (Sage et al.,  1989b).  BSA (Pentex grade; Miles 
Laboratories, Inc., Naporville, IL) and ovalbumin (Sigma Chemical Co.) 
were solubilized in TBS. Native collagen types I (lathyritic rat skin), II (bo- 
vine cartilage), III (bovine skin), IV (bovine placenta), V (human amnion), 
and VIII (bovine Descemet's membrane) were isolated as described (Sage 
et al.,  1989b).  SPARC and Tsp were prepared as described (Sage et al., 
1989b). Collagens were solub'flized in 0.1 N acetic acid, and dialyzed against 
TBS.  Solubilized proteins were coated onto microtiter wells for 4--12 h (Re- 
nmvawell  strips, Immulon; Dynatech Laboratories Inc., Alexandria, VA). 
To assay for peptides that competed for the binding of SPARC to colla- 
gens, collagen types I and III were coated on microtiter wells and additional 
binding sites were blocked with Hepes binding buffer (20 mM Hepes, 130 
Results 
Anti-peptide Antibodies Recognize SPARC in a 
Conformation-specific  Manner 
In preliminary studies,  affinity for immunizing (homolo- 
gous) peptide and for native SPARC were assessed by ELISA 
(data not shown). All sera reacted with homologous peptides 
(titers of 10-3-10  -~) but not with heterologous peptides.  Fur- 
thermore, sera did not react with BSA, ovalbumin, or 70 K 
protein (a serum protein often bound to native SPARC). Only 
anti-peptide 1.1 antibodies reacted with native SPARC in these 
assays. Antibodies displayed negligible cross-reactivity with 
heterologous peptide-rabbit serum albumin conjugates. Re- 
activity to SPARC depended on the peptide immunogen and 
did not depend on the immunized animal (n  =  2). 
To confirm these results, radioimmune precipitations were 
performed on media from PYS cells. Anti-SPARC (Fig.  1, 
lane 2) and anti-peptide  1.1  antibodies from two different 
rabbits (Fig. 1, lanes 3 and 4) precipitated SPARC as a dou- 
blet (due to differential glycosylation) from these cultures. 
Antibodies generated to other peptides did not precipitate 
the 43-kD  species (Fig.  1,  lanes 5  and 6).  Radioimmune 
precipitations of t25I-labeled SPARC were also performed. 
Precipitations with anti-SPARC and anti-peptide 1.1 antibod- 
ies precipitated 43-kD SPARC. Preincubation of  anti-peptide 
1.1  antibodies with 0.2 mM peptide 1.1  competed for this 
binding by >95 %. Antibodies against peptide 3.2 had no re- 
activity and antibodies against peptide 4.2 precipitated only 
trace amounts of the ~I-labeled SPARC (data not shown). 
Upon  reduction or certain types of denaturation, addi- 
tional  epitopes  were  exposed.  Western blots  of partially 
purified SPARC (Fig. 2 b) confirmed that unreduced SPARC 
was specifically recognized by anti-peptide  1.1  antibodies 
and to a lesser extent by anti-peptide 1.3 antibodies, but not 
by antibodies raised against other peptides. After reduction, 
SPARC was recognized by all antibodies (Fig. 2 b).  These 
results, which are summarized in Table H, suggested that the 
anti-peptide  antibodies  showed conformational specificity 
and that denatured SPARC does not display the same epi- 
topes present on the native molecule. Only the NH2 termi- 
nus of native SPARC seemed to provide an antigenic surface 
similar to that of its homologous synthetic peptide (1.1). 
Because SPARC isolated from tissues is often proteolyti- 
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jected to limited proteolysis. Fragments were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with antisera. (C) Reaction 
without enzyme; (Ti) 0.1  ~g trypsin; (T2) 2/zg trypsin. 43-kD SPARC  (SP) is cleaved to 28-kD NH2-terminal fragment and a  10-kD 
COOH-terminal fragment (arrows).  The 70-kD protein (7OK) recognized by anti-SPARC (ctSPARC) polyclonal sera is a serum protein 
structurally unrelated to SPARC (Sage et al., 1986).  Replicate blots were probed with anti-SPARC (c~SPARC)  polyclonal sera; antipeptide 
1.1 (odd); and anti-peptide  4.2 (ot4.2). (b) Samples of  SPARC were resolved by SDS-PAGE in the absence (-) or presence (+) of  a reducing 
agent (D/T) and transferred to nitrocellulose. Blots were probed serially with sera, stripped with 0.2 M glycine (pH 2.2), and reprobed. 
Blots were exposed to film for 20 h, and stripped  blots were exposed for 48 h before incubation with second antibody to ensure no carryover 
between probings. 
cally processed to a 28-kD polypeptide, we wanted to deter- 
mine whether anti-peptide antibodies could identify SPARC 
fragments. Partially purified SPARC was digested with tryp- 
sin and the proteolytic fragments were separated by SDS- 
PAGE under denaturing conditions (Fig. 2 a). Western blots 
of the resolved fragments demonstrated the specificity of the 
various  antibodies.  Anti-SPARC antibodies (oeSPARC)  re- 
acted with intact SPARC (43  kD),  the NH2-terminal frag- 
ment (a doublet at 28 kD), a  COOH-terminal fragment (10 
kD),  and  a  70-kD  serum  component  (70  K)  that  copuri- 
ties with SPARC.  Anti-peptide 1.1  (oel.1)  recognized intact 
SPARC and the 28-kD  NH2-terminal doublet but failed to 
detect the COOH-terminal fragment. Anti-peptide 4.2 (oe4.2) 
recognized intact  SPARC  and  the  COOH-terminal  10-kD 
fragment.  Consistent with the COOH-terminal location of 
region IV, anti-peptide 4.2 antibodies failed to recognize the 
NH2-terminal  fragment.  Neither  of the  anti-peptide anti- 
bodies detected the 70 K  protein. 
Anti-peptide Antibodies Block SPARC 
Peptide 1.1 antibodies blocked the anti-cell spreading activ- 
Table II. Recognition  of  SPARC by Anti-peptide Antibodies 
is Dependent on Conformation 
Antibody reactivities 
Blockll 
Native~  Reduced§  SPARC 
Immunogen  Self*  SPARC  SPARC  rounding 
1.  1.1  ++  ++  ++  ++ 
2.  1.3  ++  +/-  +  - 
3.  2.1  ++  -  +  - 
4.  3.2  ++  -  +/-  - 
5.  3.4  + +  -  +  - 
6.  4.2  ++  +/-  ++  - 
7.  SPARC  + +  + +  + +  + + 
Anti-peptide antisera specific for different regions of the SPARC molecule 
were scored  in three separate  assays foi"  their ability to bind the intact  SPARC 
protein. 
* Specific binding to each immunogen was measured by ELISA (Self). 
Binding to native SPARC was measured by an immunoprecipitation  assay. 
§ Binding to denatured SPARC was measured after reduction and Western 
blotting. 
II Ability to inhibit bioactivity of SPARC was measured by preincubating 
SPARC with antisera before adding to cells. 
(+) Positive; (-) negative. 
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SPARC-mediated anti-spreading ac- 
tivity. BAECs were plated for 24 h on 
glass coverslips in 10% heat-inacti- 
vated  FCS/DME.  Ceils  were  then 
washed in 1% heat-inactivated FCS/ 
DME,  and  treated  with  10  #g/ml 
SPARC for  4 h. (a) SPARC alone; (b) 
preincubated  with  anti-SPARC im- 
munoglobulins; (c) preincubated  with 
anti-peptide  H  immanogob,~..,;  (d) 
preincubated  with anti-peptide 4.2 
immunoglobulins.  Cells  incubated 
with  PBS alone,  or with  immtmo- 
globulins alone, were indistinguish- 
able from untreated cells  (data not 
shown). 
ity of SPARC (Fig. 3). BAEC were plated for 24 h in media 
containing  10%  heat-inactivated FCS.  After treatment for 
4 h with 10 #g/ml SPARC, most cells had assumed a rounded 
morphology (Fig.  3  a).  Pretreamaent of the  SPARC  with 
anti-SPARC antibodies (Fig. 3 b) or anti-peptide 1.1 antibod- 
ies (Fig. 3 c) blocked this activity. However, anti-peptide 4.2 
antibodies were ineffective at blocking SPARC  (Fig.  3 d). 
The fact that the anti-peptide 1.1 antibodies could neutralize 
SPARC activity suggested that the NH2 terminus of SPARC 
could participate in the anti-spreading activity of SPARC. To 
test whether peptide 1.1 or other peptides had a direct effect, 
peptides were added directly to cells in culture. 
Peptides Corresponding to Ca++-binding  Regions 
Inhibit Cell Spreading 
BAEC and FCLF were trypsinized and plated on tissue cul- 
ture  plastic  in  the  presence  of  1%  FCS  and  increasing 
amounts of peptide. Under these conditions, control BAEC 
assumed a  spread morphology within  1 h  (Fig.  4  a),  and 
FCLF within 20 rain (Fig. 4 e). In the presence of 1% FCS, 
peptide 1.1 at a concentration of 0.8 mM permitted attach- 
ment, but not spreading, of 70% of the BAEC after 3 h (Fig. 
4 b). Peptide 4.2 had a similar effect  on 85 % of the cells (Fig. 
4 d); i.e., 85 % of the cells displayed a rounded phenotype. 
The  effect was  no  longer  apparent  after  24  h  (data  not 
shown). Peptide 3.2 (Fig. 4 c), as well as peptides 1.3, 2.1, 
and 3.4 (data not shown), had no effect up to concentrations 
of 1.5 mM peptide. 
FCLF were two to five-fold more sensitive with respect to 
the anti-spreading effect ofpeptides 1.1 and 4.2. When FCLF 
were plated on dishes coated with type I collagen, 0.3 mM 
peptide  1.1  or 4.2  was  capable of inhibiting spreading in 
80-90% of the cells (Fig. 4,land h) 2.5 h after plating; in 
contrast, peptide 3.2 exhibited no effect on spreading (Fig. 4 
g). Preincubation of 1 mM peptide with homologous anti- 
peptide immunoglobulins eliminated the anti-spreading effect 
of  peptides 1.1 and 4.2 on both cell types. The use of  heterol- 
ogous antibodies  did  not block the  anti-spreading  effect. 
These observations argue strongly that the anti-spreading 
effects are due to specific actions of the peptides themselves 
and not to trace contaminants in the peptide preparations or 
to cytotoxicity. 
The dose response of BAEC to peptides was assessed by 
scoring the degree of cell reattachment and  spreading  in 
newly plated cultures. BAEC displayed a dose-dependent re- 
sponse to peptides 1.1 and 4.2, but not to inactive peptides 
or to an equivalent amount of PBS carrier (Fig. 5). 3 h after 
plating,  control cells had a rounding index of 1.12 (SE  + 
0.033) consistent with ceils that were completely spread. In 
contrast, cultures exposed to 0.6 mM peptide 1.1 had an in- 
dex of 1.39 (+0.062) that was indicative of a significant de- 
crease in cell spreading (p ~< 0.05).  1.0 mM peptide t.1 still 
permitted cell spreading,  but the process was delayed. By 
3 h, 21.1% of cells exposed to 1 mM peptide 1.1 were scored 
as spread. By 24 h, the effect of the peptide was overcome. 
For comparison, only 7.1% of cells exposed to 1.0 mM pep- 
tide 4.2 were spread at 3 h. There was no statistical differ- 
ence between  cells  treated  with  peptide  3.2  and  control 
(PBS) at 3 or 24 h. The morphological effects of all peptides 
used in this study are summarized in Table I. 
Serum Concentration and Preplating Diminished the 
Anti-spreading Activity 
Initial studies had shown that BAEC, preplated 20 h in 10% 
FCS, did not change shape in response to peptides at a con- 
centration of 0.8 mM in the presence of 2.5% FCS (see for 
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endothelial cells and fibroblasts. BAECs were plated on 
plastic dishes in 1% FCS/DME  + peptides (a, b, c, and 
d). Cells were photographed after 3 h. (a) PBS control; 
(b) 0.8 mM peptide 1.1; (c) 1.0 mM peptide 3.2; (d) 0.8 
mM peptide 4.2. FCLFs were plated on collagen coated 
dishes in 1% FCS/DME :t: peptides (e,f, g, and h). Cells 
were photographed after 2.5 h. (e) PBS control; (f) 0.3 
mM peptide 1.1; (g) 0.3 mM peptide 3.2; (h) 0.3 mM pep- 
tide 4.2. Peptides derived from other regions of SPARC 
were inactive in this assay when added at concentrations 
up to 1.5 mM (data not shown). Open arrow (=~) indi- 
cates a spread cell (group a); solid arrowhead 0Is.) indi- 
cates a cell that has begun to spread (group b); and the 
solid arrow (-.~) indicates an attached round cell that has 
not initiated spreading (group c). 
example Fig. 6, c and e). However, when the peptides Were 
presented in serum-free medium, cells rounded up and re- 
mained attached but unspread (not shown). This result sug- 
gested that serum factors, or a metabolic activity of the cells 
3 
i  1 
0.4  0.6  0.8  1.o 
Peptlde (raM) 
Figure  5.  The  antispreading 
activity ofpeptides 1.1 and 4.2 
is  dose dependent.  Peptides 
were added to BAECs mleas~ 
from their substrate by brief 
exposure to trypsin. After 3 h, 
cultures  were  photographed 
and scored for degree of cell 
spreading. A score of 3 indi- 
cates rounded cells that have 
not initiated spreading, while 
a  score  of  1 indicates  fully 
spread cells. Further details of 
the scoring  procedure are given 
in Materials and Methods. (e) 
Peptide  1.1; (*) peptide  1.3; 
(A) peptide  3.2;  (ss) peptide 
4.2; (~r) PBS control. 
supported by serum, affected the anti-spreading activity of 
the peptides. To analyze the role of cellular metabolism on 
SPARC function, we presented the SPARC and peptides to 
cells pretreated with an inhibitor of protein synthesis, cyclo- 
heximide (CHX).  CHX  (5  t~g/ml)  pretreatment inhibited 
protein synthesis by >95 %. SPARC or peptides were added 
to control BAEC or to CHX-pretreated BAEC in 2.5 % FCS, 
plus or minus CHX.  After 2  h,  cells were fixed and pho- 
tographed (Fig. 6). CHX markedly augmented the response 
to added SPARC (compare Fig. 6 a; 10/zg/ml SPARC) with 
Fig. 6 b (0.02 gg/ml SPARC). The activities of peptides 1.1 
(Fig. 6 d) and 4.2 (Fig. 6f) were also enhanced, since these 
peptides had little effect on preplated cells in the presence of 
serum (Fig. 6, c and e). CHX pretreatment had no effect on 
the morphology of control cells or on cells incubated with 
peptide 3.2 (not shown). These observations suggested that, 
while SPARC can affect metabolically active cells, it is sig- 
nificantly more active when protein synthesis is reduced. The 
failure of peptides 1.1 and 4.2 to round previously spread, 
metabolically active cells may be due to the diminished ac- 
tivities of these peptides when compared to native SPARC. 
Lane and Sage SPARC Peptides Modulate Cell Adhesion  3071 Figure 6.  Antispreading activity of 
SPARC and peptides  is  augmented 
by  inhibition  of protein  synthesis. 
BAECs were plated for 24 h on glass 
coverslips in 10% FCS/DME.  Cells 
were then preincubated for 1 h with 
2.5 % FCS/DME alone (a, c, and e), 
or in the same media containing 5/~g/ 
ml CHX for 1 h to block protein syn- 
thesis (b, d, and f). Media were then 
replaced with fresh media containing 
SPARC or peptides. After 2 h, cells 
were  fixed and  photographed.  (a) 
10  /~g/ml SPARC; (b)  0.02 /zg/ml 
SPARC; (c and d) 0.8 mM peptide 
1.1; (e and f) 0.8 mM peptide 4.2. 
Peptide 4.2 Competes  for the Binding of  SPARC 
to Puri)~,,d Collagens and Binds to Collagens in a 
Cw+-dependent Manner 
To look more closely at the interactions of SPARC with pro- 
teins in the extracellular matrix, we iodinated SPARC and 
peptides and assayed their binding to various collagen sub- 
strates in solid-phase binding assays. In competition assays, 
peptide 4.2, but not peptide I.I, competed with [~z~I]SPARC 
for binding to type llI collagen (Fig. 7 a). 46% of  the specific 
binding was competed by addition of a 50-fold molar excess 
of  peptide 4.2 over SPARC, and addition of a 250-fold molar 
excess of  peptide 4.2 competed for 59 % of the specific bind- 
ing. There was no additional competition, even when a 1,250- 
fold molar excess of  peptide 4.2 over SPARC was added (Fig. 
7 a). Similar effects were seen on type I collagen even though 
the total binding was less than that observed for type HI col- 
lagen (Table HI). Addition of 1 mM EGTA (fourfold molar 
excess over available Ca  ++  ) eliminated 100% of the specific 
binding of SPARC to these substrates. Nonspecific binding 
was 39% in this assay, deternfined with a 60-fold molar ex- 
cess of unlabeled SPARC. 
When peptides were iodinated directly, peptides 1.1 (with 
an NH2-terminal "Dyr residue added) and 3.2 failed to bind 
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Figure 7. Peptide 4.2 competes for binding of SPARC and binds to 
collagens in solid phase binding assays. [1251]Peptides and [125I]- 
SPARC were tested for  binding to various purified collagens in solid 
phase binding assays. Test proteins were bound to plastic microtiter 
wells and the remaining sites were blocked with ovalbumin. (.4) 
Wells were coated with type lII collagen. Blocked wells were then 
exposed to [t25I]SPARC, in the presence or absence of cold com- 
petitor SPARC (I), peptide 1.1 (O), or peptide 4.2 (0). Unbound 
counts were washed off and bound  t25I was determined in a 3'- 
counter. Values were expressed as percent of control after correc- 
tion for nonspecitic binding. Values are the average of  triplicate de- 
terminations. (B) Wells were coated with various collagens (I~pes 
I, II, HI, IV, V, and VIII), ovalbumin (Ov), or BSA. Blocked wells 
were then exposed to [t2Sl]peptide 4.2 in the absence of (black 
bars) or presence of (hatched bars) 5 mM CaCI2. Unbound counts 
were  subsequently washed away with  buffer containing  5  mM 
CaCI2. Bound 125I was determined in a 3,-counter. Binding is ex- 
pressed as counts per minute per 10 pmoles substrate. Numbers 
represent the average of triplicate determinations,  +  SD. 
to any of the  substrates  tested.  In contrast,  [t25I]-peptide 
4.2 bound several collagens, but did not bind other proteins 
such as BSA or ovalbumin (Fig. 7 b). In similar assays, pep- 
tide 4.2 did not bind to SPARC or fibronectin (not shown). 
Nonspecific binding of peptide 4.2 varied from 20 to 26% 
in these assays (measured by adding a 100-fold molar excess 
of unlabeled peptide). Addition of peptide 1.1 had no effect 
on the binding of peptide 4.2 to collagens (not shown). The 
binding of peptide 4.2 to collagens was dose dependent (not 
shown) and could be augmented by addition of excess Ca++ 
(Fig. 7 b and data not shown). 
In separate experiments, we have observed that peptide 4.2 
bound  [45Ca] directly (data  not shown).  The Ca++-depe  n- 
dent binding to collagens and the direct binding of [4sCa] 
suggested that the EF-hand domain of SPARC was the func- 
tional  Ca++-binding  site  reported  to  be  present  in  the 
COOH-terminal tryptic fragment of SPARC  (Domenicucci 
et al.,  1988; Sage et al.,  1989b). Moreover, these data sup- 
port the prediction that the EF-hand domain is a functional 
Ca++-binding  domain  (Engel  et  al.,  1986).  Finally,  our 
results also suggest that this domain could play a direct role 
in the binding of SPARC to collagens in the extraeellular 
matrix. 
Discussion 
Sequences from mouse, bovine, and human cDNAs show 
that SPARC is highly conserved with >95 % amino acid iden- 
tity between the mouse and human proteins (Mason et al., 
1986a; Swaroop et al.,  1988). There are no regions within 
SPARC  that appear homologous to known attachment-me- 
diating regions; e.g., RGDS (Ruoslahti and Pierschbacher, 
1987) or YIGSR sequences (Graf et al.,  1987b). With the 
exception of the Ca++-binding  regions, it has been difficult 
to predict the location of functional regions based on conser- 
vation of sequence within phylogenetically diverse SPARC 
genes, or based on comparison with unrelated sequences. 
Since SPARC is a labile protein and is difficult to purify in 
large quantity, we chose to look at synthetic peptide ana- 
logues in an effort to identify regions involved in the binding 
of SPARC to ceils and to extraceilular matrix proteins. 
In a previous study (Sage et al., 1989b), we demonstrated 
that SPARC had a specific anti-spreading effect on cultured 
BAEC. In the present study, we have extended this observa- 
tion to show that peptides corresponding to sequences in the 
two Ca++-binding domains of SPARC mimic the anti-spread- 
ing activity of the intact protein. Peptide 1.1, derived from 
the NH2-terminal Glu-rich Ca++-binding  domain, and pep- 
tide 4.2, derived from the COOH-terrninal EF-hand Ca  ++- 
Table IlL Specific binding of [12~I]SPARC to Collagen 
Substrates is Inhibited by Peptide 4. 2 
Specific  binding (SD) 
Substrate  Competitor  % 
Type I  Collagen  None  100 (0.9) 
SPARC  0.0 (1.3) 
Peptide 4.2  57.8  (35.2) 
1 mM EGTA  -3.5  (5.0) 
Type III Collagen  None  100 (9.4) 
SPARC  0.0 (8.5) 
Peptide 4.2  40.9 (6.4) 
1 mM EGTA  -0.6  (5.0) 
Substrate proteins were plated on microtiter wells and nonspecific binding sites 
were blocked with 0.1% ovalbumin. [~25I]SPARC was added in the presence 
or absence of cold competitor. Unbound radioactivity was washed away and 
bound [123I] counted in a "y counter. Measurements are averaged from three 
wells.  In  three  independent experiments,  the  average  nonspecific binding 
(NSB) was 35.6% on type I collagen and 39.1%  on type III collagen. 
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to primary cultures of endothelial cells or fibroblasts. The 
effect was dose dependent, augmented by the presence of 
CHX, and inhibited by addition of homologous antipeptide 
antibodies. Peptides from other regions of the molecule had 
no effect. Addition of FCS prevented rounding of previously 
spread cells by peptides, but ttiis effect of serum could be 
overcome by pretreating the cells with CHX. We have per- 
formed other experiments that show that the peptides them- 
selves do not markedly alter the levels of total protein syn- 
thesis, although there are alterations in the levels of mRNA 
and protein corresponding to specific macromolecules (T. E 
Lane, M. L. Iruela-Arispe and H. Sage, manuscript in prep- 
aration); the activity is therefore apparently not the result of 
cytotoxicity. 
Antibodies  raised  against peptide  1.1  blocked  SPARC- 
mediated anti-spreading activity. This result suggested that 
the NH2 terminus of the protein was required for biological 
activity. We were also interested in the structure of SPARC 
as revealed by antibodies directed against other regions of  the 
molecule. However, the pattern of anti-peptide immunoreac- 
tivity was found to be highly dependent on the conformation 
of SPARC. In fact, out of six anti-peptide antibodies raised 
in this study, only those against peptide 1.1 recognized native 
SPARC in solution. Antibodies raised against other regions 
required reduction of SPARC to expose relevant epitopes. In- 
terestingly, Mason et al. (1986a,b) described antibodies to 
a  peptide corresponding to the COOH-terminal  11  amino 
acids of murine SPARC. The sequence of this peptide does 
not overlap with peptide 4.2.  Unlike antibodies to peptide 
4.2, the antibodies to the COOH-terminal peptide immuno- 
precipitated  SPARC  from  cell  culture  media.  The  im- 
munoreactivity data suggest that the NH2-terminal Glu-rich 
region of SPARC is exposed to the solvent and maintains a 
conformation that is little affected by the remainder of the 
protein.  Since  peptide  4.2  competes  for  the  binding  of 
SPARC to collagens, it appears that this domain is exposed 
to solvent as well. Conservation of sequence and lack of im- 
munogenicity in the EF-hand domain suggest, however, that 
the exposed portion is not the sequence recognized by the an- 
tibodies we have characterized to date. 
Although  the  sequence  represented  by  peptide  3.2  is 
predicted to be antigenic by hydrophilicity analysis (Hopp 
and Woods, 1981), antibodies raised to peptide 3.2 failed to 
recognize native SPARC and reacted poorly with the dena- 
tured protein.  Tainer et al.  (1984)  have suggested that the 
cross-reactivity of anti-peptide antibodies with native protein 
is a function of the relative mobility of the corresponding site 
in  the  protein.  Their  study suggests that highly ordered 
regions would be poorly recognized by anti-peptide antibod- 
ies.  If this analysis can be extended to SPARC,  then one 
might predict that region 3 (peptide 3.2) and the EF-handlike 
domain (peptide 4.2)  are well-ordered regions of SPARC, 
whereas the NH2 and COOH termini are not. The confor- 
mational dependence shown by the antipeptide antisera used 
in this study would support a model of SPARC as a highly 
ordered protein. Most peptide epitopes were masked in the 
native structure but became exposed after reduction. A high 
degree of internal structure could help to explain the high 
percentage of conserved residues in SPARC.  More precise 
structural studies will be required to understand the native 
conformation of the SPARC protein.  Such studies will im- 
prove  our  understanding  of how  the  Ca++-binding  sites 
function in the disruption of cell-substrate contacts. 
The observation that anti-spreading activity is augmented 
by CHX is the first observation of its kind for SPARC. In- 
terestingly, blockage of protein synthesis increases the activ- 
ity of other proteins that have anti-spreading activity in en- 
dothelial cells,  such as  Tsp  (Murphy-Ullrich and  Hffk, 
1989).  Pretreatment with CHX,  followed by exposure to 
native SPARC,  resulted in a 50-100-fold increase in anti- 
spreading activity when compared to cells in which protein 
synthesis was not affected. Similar effects were seen in se- 
rum-free medium in the absence of CHX, but addition of se- 
rum to CHX-treated cells did not alter the effect seen with 
CHX alone. These data suggest the involvement of newly 
synthesized proteins required for the processing of SPARC 
or for signal transduction. Specific models of how this effect 
is mediated could include the inactivation of SPARC by a 
newly activated protease, or in the turnover of cell surface 
and extracellular matrix components bound by SPARC. The 
synthesis of inhibitors of SPARC, or of a protease activity 
that inactivates SPARC, could be important factors regulat- 
ing the concentration of SPARC needed to affect cells in vivo. 
SPARC has been recognized for its ability to bind extracel- 
lular matrix components (Termine et al., 1981; Romberg et 
al., 1985; Clezardin et al., 1988; Sage et al., 1989b).  On a 
molar basis, native SPARC binds preferentially to type III 
collagen, but also binds to other collagen types including I, 
II, IV, and V (Sage et al.,  1989b).  In the present study, we 
used the binding of SPARC to type HI collagen as an assay 
to identify peptides that could affect this process. Peptide 4.2 
competed for >50% of the binding of SPARC to type III and 
type I  collagen.  In addition, peptide 4.2  showed specific 
binding to collagens in a  Ca++-dependent  fashion, but did 
not bind albumin, ovalbumin, SPARC, or fibronectin. While 
the intact SPARC  protein discriminates among collagens, 
showing  a  preference  for type III collagen (Sage  et  al., 
1989b),  peptide 4.2 did not appear to make this distinction. 
The ability of intact SPARC to discriminate among collagens 
may thus be dependent on its three-dimensional structure. 
Other regions of the protein that contribute to the specificity 
of the collagen binding site may be required. Ongoing studies 
are being carried out with larger peptides to test this hypoth- 
esis. Our present data suggest that a COOH-terminal region 
of SPARC,  which  includes  the  Ca++-binding  site  repre- 
sented by peptide 4.2, plays a role in the binding of SPARC 
to collagens. Continued work with the peptides may identify 
other regions of SPARC that interact with components of the 
extracellular matrix, and may lead to additional insights into 
the structure of active sites within the SPARC protein itself. 
While peptide 4.2 competed for the binding of SPARC to 
collagens at concentrations within one order of magnitude of 
those required by the  intact protein,  clearly much larger 
doses of peptides were required to mimic the effects of native 
SPARC on cell spreading. The apparent requirement for high 
concentrations of  peptides, relative to those needed for activ- 
ity of the native protein, is not unique to SPARC. Peptides 
derived from the cell binding region of fibronectin (RGDS) 
and laminin (YIGSR),  at concentrations between 0.1  and 
4  mM, inhibited attachment, while nanomolar concentra- 
tions of  the native protein displayed similar efliciencies in the 
assay (Dufour et al.,  1988;  Chen et al.,  1987; Kleinman et 
al., 1989).  Studies that used peptides to map receptor bind- 
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that of the native competitor were necessary to inhibit bind- 
ing (Morris et al., 1990;  Longo et al., 1990).  The require- 
ment for such high concentrations of a fragmented protein 
is often attributed to the existence of multiple sites within 
the native protein that act synergistically to bind receptors 
(Dufour et al., 1988; Kleinman et al., 1989; Morris et al., 
1990).  In addition, peptides are likely to occur in several 
conformations in solution. We interpret the need for high 
amounts of peptide as a  direct consequence of the loss of 
cooperative sites residing in other regions of the protein and 
the diminution of conformational constraints provided by the 
native protein environment. 
Even  with  the  limitations  that  protein  fragmentation 
affords, the ability of specific peptides to modulate cell at- 
tachment is now widely appreciated. Anti-spreading activity 
has  been  reported  in  peptides  derived  from  fibronectin 
(Ruoslahti and Pierschbacher,  1986;  Dufour et al.,  1988), 
laminin (Graf et al., 1987a,b;  Kleinman et al., 1989) and in 
recombinant fragments of tenascin (Spring et al., 1989).  In 
the case of fibronectin, peptides containing the  sequence 
RGDS form the recognition site for cell surface receptors of 
the integrin class (for review, see Hynes, 1987; Ruoslahti and 
Pierschbacher, 1987).  Proteins such as yon Willebrand fac- 
tor (Dejana et al.,  1989;  Titani et al.,  1986),  fibrinogen 
(Cheresh et al.,  1989),  and asp (Lawler et al.,  1988) also 
have functional RGD-containing sequences.  Interestingly, 
while these RGD domains occur in various proteins, the pro- 
teins themselves mediate diverse spreading effects in various 
cells. These effects may be mediated by different cell surface 
receptors but are almost surely due to different properties of 
the intact proteins as well. For example, asp allows cell at- 
tachment by an RGD-dependent mechanism (Tuszynski et 
al.,  1987) but prevents spreading (Lahav, 1988;  Lawler et 
al., 1988; Murphy-Ullrich and H66k, 1989). Tenascin con- 
tains no RGD sequences but has been shown to prevent the 
interaction of fibronectin with cell surface integrins. It has 
been proposed that tenascin, by virtue of  its size and complex 
hexabrachion structure, acts by imposing a physical barrier 
between cells and their substrates (Chiquet-Ehrismann et 
al.,  1988). 
It is possible that various extracellular proteins function to 
diminish the affinity  or accessibility of  cell-extracellular ma- 
trix interactions. Given the need for high concentrations of 
many extracellular proteins (required for tissue structure and 
hydrodynamics), as well as a requirement for cells to carry 
specific receptors for these proteins, it seems reasonable to 
propose that a class of  proteins exists that modulates the abil- 
ity of cells to interact with the extracenular matrix. Negative 
modulators of cell-matrix interactions could provide a mech- 
anism for regulation of the overall level of cell-extracellular 
matrix binding without (or in concert with) the release of 
degradative enzymes or the reduction of cell surface recep- 
tors. We propose that SPARC is a new member of this class 
of  modulators, which also includes asp (Murphy-Ullrich and 
H66k, 1989) and tenascin (Chiquet-Ehrismann et al., 1988). 
SPARC contains no RGD sequences and there are no data 
to indicate that it acts via an integrin-mediated mechanism. 
The nature of the cell surface binding site for SPARC re- 
mains to be determined. 
The appearance of SPARC mRNA by day 9 of develop- 
ment in the mouse (Howe et al., 1988; Mason et al., 1986b), 
as well as the tissue distribution of SPARC mRNA and pro- 
rein (Holland et al., 1987; Wewer et al., 1988;  Sage et al., 
1989a), suggested to us that SPARC is associated with cellu- 
lar events requiring tissue remodeling, cell movement, and/ 
or proliferation. The presence of large amounts of SPARC 
in the periosteal layer of bone after day 13 of mouse develop- 
ment (Nomura et al.,  1988) and in certain invasive tumors 
(Mann et al.,  1987)  is consistent with this interpretation. 
The identification of anti-spreading activity in SPARC was 
the first function proposed that suggested a unified role for 
the protein in the various tissues and cultured cells in which 
it is seen (Sage et al., 1989b).  Thus, cells in early somites, 
gut epithelium, or remodeling bone could all require SPARC 
to modulate their interactions with extracellular matrix. We 
have now proposed that the synthesis and release of SPARC 
is one of  the options available to cells in the process of  dimin- 
ishing adhesive interactions with their substrate. The regula- 
tion of cell shape, migratory potential, and the ability to di- 
vide are only a few of the biological consequences. In the 
present study, we have confirmed the observation of anti- 
spreading activity of SPARC for BAEC and FCLF cells. We 
have also shown that unique regions of the protein may con- 
tribute to this activity by binding extracellular matrix com- 
ponents and preventing cellular spreading. We are currently 
investigating the interaction of SPARC with membrane-bound 
molecules, to identify a pathway by which the presence of 
SPARC might be linked to the regulation of specific genes. 
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